Zhitong Finance App News, China Biotech Service Holdings Co., Ltd. (“Zhongguancun Technology Service”, stock code: 08037) recently reached a strategic cooperation agreement with Zhongguancun Technology Leasing Co., Ltd. (“Zhongguancun Technology Leasing”, stock code: 01601) regarding capital requirements. Zhongguancun Technology Leasing granted Zhongguancun Technology Services a total amount of up to RMB 150 million in recyclable pre-authorized credit lines, including but not limited to direct leasing, sales and leasing investment plus commissioned operations, projects, etc.

This round of funding will mainly be used for the purchase of BNCT boron neutron medical equipment for two subsidiaries under the Chinese Medicine Service, Shanghai Longyao Biotech to build a GMP laboratory, and Hainan Pengbo Boao Boron Neutron Hospital.

Zhongguancun Technology Leasing: Formerly known as Zhongguancun Technology Leasing Co., Ltd., established in November 2012, it is a state-owned domestic financial leasing pilot enterprise approved by the Ministry of Commerce and the State Administration of Taxation. It has a registered capital of 1 billion yuan and was approved as a limited company on August 16, 2019. It is a pioneer serving Chinese technology and new economy companies. On January 21, 2020, Zhongguancun Technology Leasing was officially listed on the main board of the Hong Kong Stock Exchange Limited. Relying on Zhongguancun Development Group, Zhongguancun Technology Leasing's mission is to “promote the integration of technology and finance and achieve the dreams of technology entrepreneurs”, focusing on providing efficient financial leasing solutions and diversified consulting services for technology and new economy companies to meet the financial service needs of technology and new economy companies at different stages of development, so as to achieve the win-win development of the technology industry and the financial industry.

China Biotechnology Services Holdings Limited: A company listed on the Hong Kong Stock Exchange. Its subsidiary owns PHC Standard Pathology Laboratory Co., Ltd., which integrates comprehensive medical testing services such as pathological tests, blood biochemical tests, radiological tests, etc., and provides medical laboratory testing services and health examination services for Hong Kong private doctor groups. It is a leading diagnostic center integrating testing, physical examination and imaging in Hong Kong. Its holding subsidiary Shanghai Longyao Biotechnology Co., Ltd. was established in 2013. It is a world-leading immunocyte drug research and development enterprise with independent intellectual property rights and a national high-tech enterprise. Its wholly-owned subsidiary, Hainan Pengbo Boao Boron Neutron Hospital, introduced the world's latest radiotherapy technology, BNCT boron neutron capture therapy. It is currently building a specialist hospital in Lecheng, Hainan, and has obtained medical license and approval for the introduction of Class A large-scale equipment from the Drug Administration. The construction project was capped at the end of 2023, and is expected to open in the fourth quarter of 2024 to receive patients.